Betaplus Radiopharmaceuticals LLC - 19104 Philadelphia, PA

Business Name: Betaplus Radiopharmaceuticals LLC
Categorized In: Commercial Biotechnical Research
Address: 3160 Chestnut St # 200, Philadelphia, PA 19104
Phone Number: (215) 662-3096
Contact Person: Hank Kung
NAICS Code: 541711
SIC Code: 8731
Business Type: B2B (Business to Business)
Founding Year: 2011
Employee #: 1 to 4
Location Type: Single Location
Annual Revenue ($): $50.000 to $99.999
Share This Business:
Similar Businesses: Oncovirx - Philadelphia, PA 19104
Intervir Therapeutics - Philadelphia, PA 19104
Diathera LLC - Philadelphia, PA 19104
Pathopartitions - Philadelphia, PA 19104
Vibe Pharmaceuticals - Philadelphia, PA 19104
Biotech Studio LLC - Philadelphia, PA 19104
Aum Lifetech Inc - Philadelphia, PA 19104
Metamorphosis LLC - Philadelphia, PA 19104
Microbiota Therapeutics - Philadelphia, PA 19104
Penzymes LLC - Philadelphia, PA 19104
Navirx LLC - Philadelphia, PA 19104
Lignamed LLC - Philadelphia, PA 19104
Pathonomics - Philadelphia, PA 19104
Amyndas Biotherapeutics LLC - Philadelphia, PA 19104
Skelegen - Philadelphia, PA 19104
Cartcentric Diagnostics - Philadelphia, PA 19104
Liquid Biotech - Philadelphia, PA 19104
Epigen Cardio LLC - Philadelphia, PA 19104
Vector Biosystems - Philadelphia, PA 19104

Betaplus Radiopharmaceuticals LLC provides professional Commercial Biotechnical Research from its single location at the coordinates 39.953553,-75.18659.

The company offers B2B variables under the SIC code 8731 and NAICS code 541711, while making an annual revenue of $50.000 to $99.999 and hiring a total of 1 to 4 employees.

Founded in 2011, the company can now be visited at 3160 Chestnut St # 200, Philadelphia, Pennsylvania 19104 or contacted through representative Hank Kung at (215) 662-3096.

For frequently asked questions and further inquiries about professional Commercial Biotechnical Research, get to know more about Betaplus Radiopharmaceuticals LLC through its company website at . Engage with this business on its social media platforms through on Twitter and on Facebook.